Myelodysplastic syndromes: The role of the immune system in pathogenesis

Leukemia and Lymphoma

Volumn 52, Issue 11, 2011, Pages 2045-2049

  Warlick, Erica D ^a   Miller, Jeffrey S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Immunotherapeutic approaches; Myeloid leukemias, dysplasias; NK cell biology; T cell mediated immunity

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; LENALIDOMIDE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2D;

DRUG EFFICACY; DRUG EXPOSURE; HUMAN; IMMUNE DYSREGULATION; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; IN VITRO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTOTOXICITY; MYELODYSPLASTIC SYNDROME; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; SURVIVAL RATE;

CYTOKINES; DISEASE PROGRESSION; HUMANS; IMMUNE SYSTEM; INFLAMMATION MEDIATORS; KILLER CELLS, NATURAL; MYELODYSPLASTIC SYNDROMES; MYELOID CELLS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 80054967360     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.584002     Document Type: Review

References (37)

1. Marisavljevic D, Kraguljac N, Rolovic Z. Immunologic abnormalities in myelodysplastic syndromes: clinical features and characteristics of the lymphoid population. Med Oncol 2006;23:385-392.
2. Billstrom R, Johansson H, Johansson B, Mitelman F. Immunemediated complications in patients with myelodysplastic syndromes-clinical and cytogenetic features. Eur J Haematol 1995;55:42-48.
3. Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 2001;25:1075-1083.
4. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998;102:1314-1322.
5. Melenhorst JJ, Eniafe R, Follmann D, Nakamura R, Kirby M, Barrett AJ. Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. Br J Haematol 2002;119:97-105.
6. Miller JS. Biology of natural killer cells in cancer and infection. Cancer Invest 2002;20:405-419.
7. Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res 2003;90:127-156.
8. Kiladjian JJ, Bourgeois E, Lobe I, et al. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia 2006;20:463-470.
9. Epling-Burnette PK, Bai F, Painter JS, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 2007;109:4816-4824.
10. Carlsten M, Baumann BC, Simonsson M, et al. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34(+) blasts in myelodysplastic syndrome. Leukemia 2010;24: 1607-1616.
11. Smith MA, Smith JG. The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. Leuk Res 1991;15: 597-601.
12. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997;99:699-705.
13. Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998;100:304-309.
14. Epling-Burnette PK, Painter JS, Rollison DE, et al. Prevalence and clinical association of clonal T-cell expansions in myelodysplastic syndrome. Leukemia 2007;21:659-667.
15. Kordasti SY, Ingram W, Hayden J, et al. CD4+CD25high Foxp3+regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007;110:847-850.
16. Hamdi W, Ogawara H, Handa H, Tsukamoto N, Nojima Y, Murakami H. Clinical significance of regulatory T cells in patients with myelodysplastic syndrome. Eur J Haematol 2009;82:201-207.
17. Kotsianidis I, Bouchliou I, Nakou E, et al. Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+regulatory T cells in myelodysplastic syndromes (MDS). Leukemia 2009;23:510-518.
18. Alfinito F, Sica M, Luciano L, et al. Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes. Br J Haematol 2010;148:90-98.
19. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokineinduced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010;185:2273-2284.
20. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-174.
21. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006;16:53-65.
22. Ugel S, Delpozzo F, Desantis G, et al. Th erapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 2009; 9:470-481.
23. Serafini P, MgebroffS, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008;68:5439-5449.
24. McCormack SE, Warlick ED. Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine. Onco Targets Th er 2010;3:157-165.
25. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-2440.
26. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:3895-3903.
27. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-232.
28. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-1465.
29. Tang KF, He CX, Zeng GL, et al. Induction of MHC class I-related chain B (MICB) by 5-aza-2 '-deoxycytidine. Biochem Biophys Res Commun 2008;370:578-583.
30. Liu Y, Kuick R, Hanash S, Richardson B. DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors. Clin Immunol 2009;130:213-224.
31. Santourlidis S, Trompeter HI, Weinhold S, et al. Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J Immunol 2002;169: 4253-4261.
32. Gao XN, Lin J, Wang LL, Yu L. Demethylating treatment suppresses natural killer cell cytolytic activity. Mol Immunol 2009; 46:2064-2070.
33. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005;128:192-203.
34. Chan AC, Neeson P, Leeansyah E, et al. Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients. Leukemia 2010;24:592-600.
35. Passweg JR, Giagounidis AAN, Simcock M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33/99. J Clin Oncol 2011;29:303-309.
36. Sloand EM, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia with immunosuppressive therapy. J Clin Oncol 2008;26:2505-2511.
37. Olnes MJ, Sloand EM. Targeting immune dysregulation in myelodysplastic syndromes. JAMA 2011;305:814-819.